Literature DB >> 9162094

Sequence and expression of mouse proteasome activator PA28 and the related autoantigen Ki.

H Jiang1, J J Monaco.   

Abstract

Using reverse transcription polymerase chain reaction, we cloned and sequenced full-length mouse cDNAs for the two homologous subunits of the proteasome activator PA28 (PA28alpha and PA28beta), as well as for the related protein Ki. These proteins are highly conserved among species. Northern blot analysis of PA28a, PA28b, and Ki mRNA demonstrated broad tissue distribution. Although single transcripts were detected for PA28a and PA28b, two different sized transcripts were detected for mouse Ki, suggesting either alternative splicing or alternate polyadenylation sites. The levels of these transcripts increased in response to interferon-gamma (IFN-gamma) treatment in mouse H6 hepatoma cells, although PA28a and PA28b were induced to a greater extent than Ki, and the effect of IFN-gamma stimulation on Ki expression was transient. Southern blot analysis suggests that both PA28a and PA28b are multiple-copy genes, while Ki is a single-copy gene.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9162094     DOI: 10.1007/s002510050246

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  12 in total

Review 1.  The immunoproteasome as a target in hematologic malignancies.

Authors:  Deborah J Kuhn; Robert Z Orlowski
Journal:  Semin Hematol       Date:  2012-07       Impact factor: 3.851

2.  Progression of cancer from indolent to aggressive despite antigen retention and increased expression of interferon-gamma inducible genes.

Authors:  Terry H Wu; Karin Schreiber; Ainhoa Arina; Nikolai N Khodarev; Elena V Efimova; Donald A Rowley; Ralph R Weichselbaum; Hans Schreiber
Journal:  Cancer Immun       Date:  2011-06-30

Review 3.  The proteasome activator 11 S REG (PA28) and class I antigen presentation.

Authors:  M Rechsteiner; C Realini; V Ustrell
Journal:  Biochem J       Date:  2000-01-01       Impact factor: 3.857

4.  Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.

Authors:  Deborah J Kuhn; Sally A Hunsucker; Qing Chen; Peter M Voorhees; Marian Orlowski; Robert Z Orlowski
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

5.  Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome.

Authors:  Xueyan Chen; Lance F Barton; Yong Chi; Bruce E Clurman; James M Roberts
Journal:  Mol Cell       Date:  2007-06-22       Impact factor: 17.970

6.  Differential influence on cytotoxic T lymphocyte epitope presentation by controlled expression of either proteasome immunosubunits or PA28.

Authors:  A Sijts; M Camps; R Offringa; C Melief; P M Kloetzel; F Ossendorp
Journal:  J Exp Med       Date:  2000-08-21       Impact factor: 14.307

Review 7.  The immunoproteasome and viral infection: a complex regulator of inflammation.

Authors:  Mary K McCarthy; Jason B Weinberg
Journal:  Front Microbiol       Date:  2015-01-29       Impact factor: 5.640

Review 8.  PA28αβ: the enigmatic magic ring of the proteasome?

Authors:  Paolo Cascio
Journal:  Biomolecules       Date:  2014-06-19

9.  Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients.

Authors:  Swetlana Mactier; Kimberley L Kaufman; Penghao Wang; Ben Crossett; Gulietta M Pupo; Philippa L Kohnke; John F Thompson; Richard A Scolyer; Jean Y Yang; Graham J Mann; Richard I Christopherson
Journal:  Pigment Cell Melanoma Res       Date:  2014-08-14       Impact factor: 4.693

Review 10.  PA28γ, an Accomplice to Malignant Cancer.

Authors:  Kexin Lei; Hetian Bai; Silu Sun; Chuan Xin; Jing Li; Qianming Chen
Journal:  Front Oncol       Date:  2020-10-30       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.